Currently, several anti-HER2 agents are available at ABUH (trastuzumab, pertuzumab, and trastuzumab emtansine), however, these agents are frequently interrupted, and several targeted agents used to treat BC or other cancers do not exist because of a lack of resources (41). Here, ERBB2 is linked to breast cancer.